AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 131.00 Increased By ▲ 1.47 (1.13%)
BOP 6.75 Increased By ▲ 0.07 (1.05%)
CNERGY 4.65 Increased By ▲ 0.02 (0.43%)
DCL 9.00 Increased By ▲ 0.06 (0.67%)
DFML 43.35 Increased By ▲ 1.66 (3.98%)
DGKC 83.81 Increased By ▲ 0.04 (0.05%)
FCCL 32.98 Increased By ▲ 0.21 (0.64%)
FFBL 77.98 Increased By ▲ 2.51 (3.33%)
FFL 11.51 Increased By ▲ 0.04 (0.35%)
HUBC 111.00 Increased By ▲ 0.45 (0.41%)
HUMNL 14.56 No Change ▼ 0.00 (0%)
KEL 5.44 Increased By ▲ 0.05 (0.93%)
KOSM 8.45 Increased By ▲ 0.05 (0.6%)
MLCF 39.97 Increased By ▲ 0.18 (0.45%)
NBP 60.75 Increased By ▲ 0.46 (0.76%)
OGDC 198.50 Decreased By ▼ -1.16 (-0.58%)
PAEL 26.66 Increased By ▲ 0.01 (0.04%)
PIBTL 7.90 Increased By ▲ 0.24 (3.13%)
PPL 159.00 Increased By ▲ 1.08 (0.68%)
PRL 26.50 Decreased By ▼ -0.23 (-0.86%)
PTC 18.80 Increased By ▲ 0.34 (1.84%)
SEARL 82.81 Increased By ▲ 0.37 (0.45%)
TELE 8.41 Increased By ▲ 0.10 (1.2%)
TOMCL 34.80 Increased By ▲ 0.29 (0.84%)
TPLP 9.15 Increased By ▲ 0.09 (0.99%)
TREET 17.50 Increased By ▲ 0.03 (0.17%)
TRG 61.90 Increased By ▲ 0.58 (0.95%)
UNITY 27.43 Decreased By ▼ -0.01 (-0.04%)
WTL 1.40 Increased By ▲ 0.02 (1.45%)
BR100 10,407 No Change 0 (0%)
BR30 31,713 No Change 0 (0%)
KSE100 97,957 Increased By 629.1 (0.65%)
KSE30 30,384 Increased By 191.6 (0.63%)

Canada on Thursday approved Novavax Inc's COVID-19 vaccine for people aged 18 years and older, making it the fifth such shot to be cleared for use in the country.

The vaccine's safety and effectiveness in people younger than 18 years have not yet been established, Health Canada said in a statement.

Canada has committed to purchase 52 million doses of the vaccine, with an option to buy up to 24 million doses more.

Novavax's recombinant protein vaccine, Nuxavoxid, uses a more established technology than mRNA, the novel method behind the two most commonly used COVID-19 vaccines - from Pfizer /BioNTech and Moderna.

Some experts have voiced hopes that Novavax's product could convince as-yet unvaccinated people who are sceptical about the novel mRNA technology to get a shot.

Britain gets fifth COVID vaccine after Novavax approval

On Wednesday, Novavax Chief Commercial Officer John Trizzino said there is still significant demand for vaccination across the globe, especially in light of Omicron, the threat of more variants and a high percentage of unvaccinated people who need primary vaccination.

"We also know that many of the booster programs that are in process right now will drive demand for our product."

However, the company has been plagued by supply and manufacturing issues as well as regulatory delays.

It has delivered just a small fraction of the 2 billion COVID-19 shots it plans to supply worldwide in 2022, after delaying first-quarter shipments in Europe and some lower income countries.

The company expects to supply 27 million doses of its vaccine to Europe in the first quarter, but did not provide guidance on how many overall doses it plans to ship during the period.

Novavax's protein-based vaccine is being reviewed by the U.S. Food and Drug Administration and has received approvals from the European Union and the World Health Organization.

Comments

Comments are closed.